On 7 June 2024, the VRI initiated further commercialization of its research results by signing an agreement with Reform Therapeutics CZ, s.r.o. on the joint development of a new preparation for mucosal administration of active substances. This collaboration builds on the results of the project entitled "FIT - Pharmacology, Immunotherapy, (nano)Toxicology", which was funded within the call Support of excellent research teams of the Operational Programme Research, Development, and Innovation under the No. CZ.02.1.01/0.0/0.0/15_003/0000495. This project was implemented at the Institute between 2016 and 2022. The project focused on the comprehensive study of biocompatible nanoparticles and their use in the field of biomedicine, particularly in the development of recombinant vaccines, targeted therapeutics (antivirals, cytostatics), and theranostics. Besides achieving all planned monitoring indicators, the project implementation also involved construction modifications of selected facilities within the Institute's premises. These facilities have been prepared for conducting small batch production processes under the appropriate quality assurance regime.
The VRI's critical responsibilities include providing formulation work, conducting preclinical pharmacokinetic and pharmacodynamic experiments, prototype production and conducting stability studies.
The new formulation will also be the subject of an international patent application. The new products are expected to be on the market as early as 2026.
